Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. The growing health concern of fatty liver disease

The growing health concern of fatty liver disease

Stories Sep 20, 2019 3 minutes

Prevention and medical innovation are needed to stem the growth of a disease that has few symptoms but can lead to permanent liver damage.

Physicians like Vancouver Coastal Health Research Institute researcher, Dr. Eric Yoshida, are concerned that rates of non-alcoholic fatty liver disease (NAFLD) and its more severe progression, non-alcoholic steatohepatitis (NASH), are on the rise while medications are still in the development stages.

Around 20 per cent  of Canadians are affected NAFLD1—an accumulation of fat in liver cells—making it the most common liver disease in Canada2.  NASH affects four per cent  of the Canadian population3—almost 1.5 million individuals.

Dr. Eric Yoshida is a professor of medicine at the University of British Columbia and the Division of Gastroenterology at Vancouver General Hospital.

“NASH causes inflammation in the liver, which causes liver damage, which will accumulate into cirrhosis [scarring of the liver], which is a risk factor for liver cancer,” says Yoshida. “Patients with NASH are at greater risk of needing a liver transplant, which is why we are looking for medications to help reduce inflammation caused by NASH and prevent the worsening of symptoms.”

No approved medications to treat NAFLD or NASH presently exist in Canada or the United States. Although there is a dire need for them. 

Each year Yoshida sees more patients with end-stage cirrhosis of the liver caused by NASH present to the Liver Transplant Program at Vancouver General Hospital (VGH)—where he has worked since 1991. 

“The magnitude of the problem nationally and globally is huge. If the number of patients with NASH continues to grow, transplant programs may become overwhelmed.” 

Yoshida is currently investigating two different mediations—Elafibranor and Obeticholic Acid—to treat the inflammation and liver damage caused by NASH. 

“I think there is some promise in these medications and others being investigated,” he says, “but we are still in the early days of NASH pharmacologic research.” 

Raising awareness about lifestyle choices that lead to liver damage

Unlike alcohol-related liver damage, NAFLD and NASH are mostly linked to poor diet, obesity and sedentary behaviour—which have also been on the rise4.  Other risk factors include diabetes, high blood pressure, elevated fat levels in the blood, hepatitis B and C and a person’s genes.

“Most patients are asymptomatic and only upon receiving an ultrasound is it discovered that they have a fatty liver.”

Diagnosis usually happens when a doctor identifies risk factors, or when a patient receives an ultrasound for unrelated reasons and the radiologist discovers fatty infiltrations on the liver—the trademark of NAFLD and NASH.

Preventing NAFLD and NASH requires lifestyle changes and, often, losing weight, says Yoshida. 

“NAFLD can go into remission if patients adhere to a healthy diet and regular exercise.” 

Yoshida uses a FibroScan machine to demonstrate to patients the severity of their condition and why they may need to make lifestyle changes to improve it—the Division of Gastroenterology at VGH acquired one in 2018. The machine bounces sound waves around the liver to quantify the degree of fatty liver disease and predict how it could progress.

Raising awareness about the severity of NAFLD and NASH is no small feat. According to a March 2019 Cision poll, 89 per cent of Canadians have “little to no knowledge” of NAFLD5. 

“We need to increase public awareness and education about eating healthy and exercising,” says Yoshida. Those, he adds, are the two best measures to prevent liver disease that anybody can take.


1 Non-alcoholic steatohepatitis (NASH)
2 Liver Disease in Canada - A Crisis in the Making
3 Non-alcoholic steatohepatitis (NASH)
4 Canada’s obesity rate has doubled since the 1970s. What happened? and Time to curb our appetite for ultra-processed food
5 Poll: Over half of Canadians are unaware the most common liver disease in Canada could lead to liver cancer, death.

Researchers

Eric Yoshida

Related Articles

Removing barriers to liver transplantation in COVID-19-postive patients

Ask an expert: Even though I don’t drink alcohol, do I still need to worry about liver disease?

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Celebrating the life and distinguished career of Dr. Marcel Dvorak

May 14, 2025
Type
Stories

More equitable representation needed in Parkinson’s research

May 9, 2025 parkinsons, patient engagement, women
Type
Stories

Gamified stroke recovery improves arm function

May 8, 2025 stroke, rehabilitation
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy